Research Focus Areas
Custom Synthesis of Metal/Porous Nanoparticles
Nanotoxicology
Biomedical Image Contrast Agents
Precision Nanoprobes
Molecular Nanotechnology
Custom Synthesis of Metal/Porous Nanoparticles
Standardized synthesis of Gold nanoparticles (nanoclusters, 5 nm, 10 nm, 16 nm) Silver nanoparticles (nanoclusters, 10 nm, 40 nm, 95 nm) Iron oxide nanoparticles (10 nm) Gadolinium oxide (5 nm, 10 nm) Hafnium oxide (5 nm, 10 nm) Microporous silica particles (15 nm, 50 nm, 100 nm, 400 nm) Other nanoparticles currently being optimized include …
Nanotoxicology
Nanotoxicity assessment is an integral part of designing biomedical probes. In vitro toxicity of nanoparticles is assessed using murine (L929) and human cell lines (HUVEC, RAW246.7). In vivo toxicity was assessed in zebrafish models, and in vivo biodistribution/blood pool kinetics was assessed in athymic and euthymic mouse models. Representative Publications …
Biomedical Image Contrast Agents
Scaled up the synthesis of nanoparticle contrast agents. I specialize in the synthesis of long emission lifetime, fluorescent and photoluminescent nanoparticles. This is achieved by modifying Au cores with fluorophore embedded shells or Au nanoclusters with tunable photoluminescence. Fluorescent silica particles with sizes ranging from 15 nm to 400 nm are also available. Such probes …
Precision Nanoprobes
Antibody-drug conjugates are emerging as a frontrunner in precision targeted therapeutics. However, this capability is still beyond the ability of most academic laboratories. The primary reason for this is the need to identify a precise binding site on the constant region of the antibody (Fc) for the drug molecule to be conjugated, while not affecting …
Molecular Nanotechnology
This is the current focus of my research. Utilizing anisotropic and hybrid nanoparticle architectures to introduce directionality in motion, precisely orienting targeting molecules and directed exertion of force by nanosystems. Anisotropic nanoparticles can be Janus hybrids or non-spherical nanoparticles and include rods, plates, prisms, and core-shells. This will lay the basis for nanomotors and nanomachines …
2025 in Review: Innovation, Funding, and Student Success
2025 has been a landmark year for the Nallathamby Laboratory. From securing major federal funding to advancing our intellectual property and celebrating student milestones, our team has made significant strides in nanomedicine and precision health. Here is a look back at our key achievements. Protecting Our Innovations: Three New Patent Applications It has been a …
Precision Chemotherapy: Externally Controlled Nanocarriers for Aggressive Cancers
Aggressive malignancies like triple-negative breast cancer (TNBC), ovarian cancer, and prostate cancer remain difficult to treat because they often lack the surface receptors required for traditional targeted therapies. Standard treatments like doxorubicin (Dox) are effective at killing cancer but cause severe systemic side effects, most notably cardiotoxicity. To overcome these barriers, the Nallathamby Lab at …
NIH Funding Opportunities
- Request for Information (RFI): Development of Disease Modifying Drugs to Prevent or Treat Specific Aging-Related Conditions December 23, 2025Notice NOT-AG-26-001 from the NIH Guide for Grants and Contracts
- Notice of Announcement of NIH Oligonucleotide Toxicity (OligoTox) Open Data Challenge Competition December 22, 2025Notice NOT-TR-26-006 from the NIH Guide for Grants and Contracts
- Intramural Loan Repayment Program for General Research for ACGME Fellows (ACGME-LRP) December 22, 2025Notice NOT-OD-26-016 from the NIH Guide for Grants and Contracts
- Intramural Loan Repayment Program for General Research (GR-LRP) December 22, 2025Notice NOT-OD-26-015 from the NIH Guide for Grants and Contracts
- Intramural Loan Repayment Program for Clinical Researchers from Disadvantaged Backgrounds (CR-LRP) December 22, 2025Notice NOT-OD-26-014 from the NIH Guide for Grants and Contracts
- Intramural Loan Repayment Program for AIDS Research (AIDS-LRP) December 22, 2025Notice NOT-OD-26-013 from the NIH Guide for Grants and Contracts
Recent Comments